Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

BACKGROUND: Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of participants’ self-reported symptoms in the MOVe-OUT trial, which evaluated molnupiravir initiate...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yanfen, Puenpatom, Amy, Johnson, Matthew G, Zhang, Ying, Zhao, Yujie, Surber, Joseph, Weinberg, Aaron, Brotons, Carlos, Kozlov, Roman, Lopez, Rudy, Coetzee, Kathleen, Santiaguel, Joel, Du, Jiejun, Williams-Diaz, Angela, Brown, Michelle, Paschke, Amanda, De Anda, Carisa, Norquist, Josephine M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686947/
https://www.ncbi.nlm.nih.gov/pubmed/37466374
http://dx.doi.org/10.1093/cid/ciad409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686947/
https://www.ncbi.nlm.nih.gov/pubmed/37466374
http://dx.doi.org/10.1093/cid/ciad409

Ejemplares similares